Once-weekly Insulin Icodec With Dosing Guide App Shows Superior HbA1C Reduction Versus Once-Daily Insulin In Pivotal Phase 3a Trial
28 Sept 2023 • In the Phase 3a ONWARDS 5 randomized trial, once-weekly insulin icodec titrated with a dosing guide app demonstrated superior reduction in HbA1c levels and similarly low hypoglycemia rates compared with once-daily insulin. The findings are published in Annals of Internal Medicine.
- This study, conducted over 52 weeks and involving 1085 insulin-naive adults with T2D across multiple countries, aimed to compare the effectiveness and safety of once-weekly insulin icodec (icodec) titrated using a dosing guide app (icodec with app) versus the standard practice of once-daily basal insulin analogues (OD analogues).
- The primary outcome measure was the change in glycated hemoglobin (HbA1c) levels from baseline to week 52.
- The results revealed that icodec with the app led to a greater reduction in HbA1c levels compared to OD analogues, with the superiority confirmed through statistical analysis.
- Additionally, patient-reported outcomes, including treatment satisfaction and compliance, were more favorable with icodec with the app. Importantly, both treatments exhibited low and similar rates of clinically significant or severe hypoglycemia.
- One limitation of the study was the inability to distinguish the specific effects of icodec from those of the dosing guide app.
In conclusion, compared with OD analogues, icodec with app showed superior HbA1c reduction and improved treatment satisfaction and compliance with similarly low hypoglycemia rates.
Source: Annals of Internal Medicine | Read full story